Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Amazon Explores AI Content Marketplace With Media Publishers 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Pompano Beach, FL, March 13, 2018 -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
Dr. Felix Amon has two decades of product management, medical innovation and business development experience in healthcare and related industries, including three years as a Product Manager for Eli Lilly, 2 years as as the Austria Marketing and Sales Director for Merck (MSD) Europe, followed by leading the Ophthalmics business in Merck’s ww Headquarter in Whitehouse Station, New Jersey where he managed Planning and Project Management for a $650 million business operating in 104 countries. He also completed the development of an European Sales and Marketing Campaign for BIOGEN’s Avonex and implemented the launch of Avonex in Germany, Austria and Switzerland. Dr. Amon has an MBA (1987) from Emory University in Atlanta, Georgia, and a PhD in Law (1985) from Linz – Johannes Keppler University in Austria.
BSEM’s, COO, Andrew Van Vurst stated, “The addition of Dr. Amon to our team is imperative in the Companies’ mission to discover, develop and market novel Pharmaceutical and Regenerative Medicine products. We look forward to leveraging his experience in the development of sales and marketing strategies for BioStem Technologies pharmaceutical portfolio.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risk factors, as discussed in reports filed by the Company with OTC Markets.
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: [email protected] Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst [email protected] (954) 380-8342
